Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tony R Reid

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
In Vivo (Athens, Greece)|June 28, 2021
A Patient-Derived Orthotopic Xenograft Model of Gastroesophageal-Junction Adenocarcinoma Translated to the Clinic by Tumor-Targeting Fluorescent Antibodies to Carcinoembryonic-Antigen-Related Cell-Adhesion MoleculesMichael A Turner, Siamak Amirfakhri, Hiroto Nishino, et al.
Anticancer Research|March 10, 2015
Phase I study of everolimus, cetuximab and irinotecan as second-line therapy in metastatic colorectal cancerJ Randolph Hecht, Tony R Reid, Christopher R Garrett, et al.
Oncoimmunology|November 11, 2017
No patient left behind: The promise of immune priming with epigenetic agentsCorey A Carter, Bryan T Oronsky, Joseph Roswarski, et al.
Journal of Medicinal Chemistry|May 27, 2021
Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical DevelopmentBryan Oronsky, XiaoNing Guo, XiaoHui Wang, et al.
American Journal of Cancer Research|October 13, 2022
Subset analysis of safety and efficacy in asian patients treated with RRx-001 across three clinical trialsXiaoning Guo, Xiaohui Wang, Sui Shen, et al.
Case Reports in Oncology|April 12, 2016
Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001Corey A Carter, Bruno Schmitz, P Gabriel Peterson, et al.
Biomolecules|July 8, 2016
Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming AgentsBryan Oronsky, Jan Scicinski, Michelle M Kim, et al.
Human Gene Therapy|May 22, 2010
Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liverSunil K Geevarghese, David A Geller, Hans A de Haan, et al.
Frontiers in Oncology|July 1, 2015
Episensitization: Defying Time's ArrowBryan T Oronsky, Arnold L Oronsky, Michelle Lybeck, et al.
Oncology Research and Treatment|November 18, 2016
Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case ReportChristina Brzezniak, Bryan Oronsky, Jan Scicinski, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
In Vivo (Athens, Greece)|June 28, 2021
A Patient-Derived Orthotopic Xenograft Model of Gastroesophageal-Junction Adenocarcinoma Translated to the Clinic by Tumor-Targeting Fluorescent Antibodies to Carcinoembryonic-Antigen-Related Cell-Adhesion MoleculesMichael A Turner, Siamak Amirfakhri, Hiroto Nishino, et al.
Anticancer Research|March 10, 2015
Phase I study of everolimus, cetuximab and irinotecan as second-line therapy in metastatic colorectal cancerJ Randolph Hecht, Tony R Reid, Christopher R Garrett, et al.
Oncoimmunology|November 11, 2017
No patient left behind: The promise of immune priming with epigenetic agentsCorey A Carter, Bryan T Oronsky, Joseph Roswarski, et al.
Journal of Medicinal Chemistry|May 27, 2021
Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical DevelopmentBryan Oronsky, XiaoNing Guo, XiaoHui Wang, et al.
American Journal of Cancer Research|October 13, 2022
Subset analysis of safety and efficacy in asian patients treated with RRx-001 across three clinical trialsXiaoning Guo, Xiaohui Wang, Sui Shen, et al.
Case Reports in Oncology|April 12, 2016
Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001Corey A Carter, Bruno Schmitz, P Gabriel Peterson, et al.
Biomolecules|July 8, 2016
Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming AgentsBryan Oronsky, Jan Scicinski, Michelle M Kim, et al.
Human Gene Therapy|May 22, 2010
Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liverSunil K Geevarghese, David A Geller, Hans A de Haan, et al.
Frontiers in Oncology|July 1, 2015
Episensitization: Defying Time's ArrowBryan T Oronsky, Arnold L Oronsky, Michelle Lybeck, et al.
Oncology Research and Treatment|November 18, 2016
Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case ReportChristina Brzezniak, Bryan Oronsky, Jan Scicinski, et al.
Pageof 6